US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
JPS54113492A
(en)
|
1978-02-24 |
1979-09-05 |
Sanyo Chem Ind Ltd |
Preparation of glucoprotein derivative
|
US4356170A
(en)
|
1981-05-27 |
1982-10-26 |
Canadian Patents & Development Ltd. |
Immunogenic polysaccharide-protein conjugates
|
US4757006A
(en)
|
1983-10-28 |
1988-07-12 |
Genetics Institute, Inc. |
Human factor VIII:C gene and recombinant methods for production
|
US4970300A
(en)
|
1985-02-01 |
1990-11-13 |
New York University |
Modified factor VIII
|
US5250421A
(en)
|
1986-01-03 |
1993-10-05 |
Genetics Institute, Inc. |
Method for producing factor VIII:C-type proteins
|
US5198349A
(en)
|
1986-01-03 |
1993-03-30 |
Genetics Institute, Inc. |
Method for producing factor VIII:C and analogs
|
JPH0387173A
(ja)
|
1987-09-10 |
1991-04-11 |
Teijin Ltd |
ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体
|
US5153265A
(en)
|
1988-01-20 |
1992-10-06 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
US4966999A
(en)
|
1988-06-07 |
1990-10-30 |
Cytogen Corporation |
Radiohalogenated compounds for site specific labeling
|
US5122614A
(en)
|
1989-04-19 |
1992-06-16 |
Enzon, Inc. |
Active carbonates of polyalkylene oxides for modification of polypeptides
|
SE465222C5
(sv)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
SE466754B
(sv)
|
1990-09-13 |
1992-03-30 |
Berol Nobel Ab |
Saett att kovalent binda biopolymerer till hydrofila ytor
|
WO1992008790A1
(en)
|
1990-11-14 |
1992-05-29 |
Cargill, Incorporated |
Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
|
WO1992016555A1
(en)
|
1991-03-18 |
1992-10-01 |
Enzon, Inc. |
Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
|
US5846951A
(en)
|
1991-06-06 |
1998-12-08 |
The School Of Pharmacy, University Of London |
Pharmaceutical compositions
|
US6037452A
(en)
|
1992-04-10 |
2000-03-14 |
Alpha Therapeutic Corporation |
Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
|
AU5098193A
(en)
|
1992-09-01 |
1994-03-29 |
Berlex Laboratories, Inc. |
Glycolation of glycosylated macromolecules
|
DK0627924T3
(da)
|
1992-10-02 |
2001-04-30 |
Genetics Inst |
Sammensætning, der omfatter koagulationsfaktor VIII formulering, fremgangsmåde til dens fremstilling og anvendelse af et overfladeaktivt middel som stabilisator
|
NZ250375A
(en)
|
1992-12-09 |
1995-07-26 |
Ortho Pharma Corp |
Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
|
US5298643A
(en)
|
1992-12-22 |
1994-03-29 |
Enzon, Inc. |
Aryl imidate activated polyalkylene oxides
|
WO1994015625A1
(en)
|
1993-01-15 |
1994-07-21 |
Enzon, Inc. |
Factor viii - polymeric conjugates
|
US5621039A
(en)
|
1993-06-08 |
1997-04-15 |
Hallahan; Terrence W. |
Factor IX- polymeric conjugates
|
SE504074C2
(sv)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
US6869930B1
(en)
|
1993-09-17 |
2005-03-22 |
Novo Nordisk A/S |
Acylated insulin
|
BR9407508A
(pt)
|
1993-09-17 |
1997-01-07 |
Novo Nordisk As |
Derivado de insulina composição farmaceutica e processo para o tratamento de diabete em um paciente com necessidade deste tratamento
|
US6011007A
(en)
|
1993-09-17 |
2000-01-04 |
Novo Nordisk A/S |
Acylated insulin
|
EP0788375A2
(en)
|
1994-11-09 |
1997-08-13 |
Robin Ewart Offord |
Functionalized polymers for site-specific attachment
|
WO1996040662A2
(en)
|
1995-06-07 |
1996-12-19 |
Cellpro, Incorporated |
Aminooxy-containing linker compounds and their application in conjugates
|
AU6255096A
(en)
|
1995-06-07 |
1996-12-30 |
Mount Sinai School Of Medicine Of The City University Of New York, The |
Pegylated modified proteins
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
US5866538A
(en)
|
1996-06-20 |
1999-02-02 |
Novo Nordisk A/S |
Insulin preparations containing NaCl
|
WO1998049198A1
(en)
|
1997-04-30 |
1998-11-05 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
US6183738B1
(en)
|
1997-05-12 |
2001-02-06 |
Phoenix Pharamacologics, Inc. |
Modified arginine deiminase
|
CA2292760A1
(en)
|
1997-06-04 |
1998-12-10 |
Oxford Biomedica (Uk) Limited |
Vector
|
WO1999003496A1
(en)
|
1997-07-21 |
1999-01-28 |
The University Of North Carolina At Chapel Hill |
Factor ix antihemophilic factor with increased clotting activity
|
DE59813187D1
(de)
|
1997-12-03 |
2005-12-15 |
Roche Diagnostics Gmbh |
Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung
|
US5985263A
(en)
|
1997-12-19 |
1999-11-16 |
Enzon, Inc. |
Substantially pure histidine-linked protein polymer conjugates
|
US6596398B1
(en)
|
1998-08-21 |
2003-07-22 |
Atofina Chemicals, Inc. |
Solar control coated glass
|
AU764144B2
(en)
|
1998-08-28 |
2003-08-14 |
Gryphon Therapeutics, Inc. |
Polyamide chains of precise length, methods to manufacture them and their conjugates
|
EP1656952B1
(en)
|
1998-10-16 |
2013-12-18 |
Biogen Idec MA Inc. |
Polyalkylene glycol conjugates of interferon beta-1A and uses thereof
|
DE19852729A1
(de)
|
1998-11-16 |
2000-05-18 |
Werner Reutter |
Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
|
BR0008405B1
(pt)
|
1999-02-22 |
2014-04-22 |
Baxter Int |
Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
|
AU779887B2
(en)
*
|
1999-06-08 |
2005-02-17 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising aminooxy groups
|
US6531122B1
(en)
|
1999-08-27 |
2003-03-11 |
Maxygen Aps |
Interferon-β variants and conjugates
|
US7230081B1
(en)
|
1999-11-12 |
2007-06-12 |
Maxygen Holdings, Ltd. |
Interferon gamma conjugates
|
US7074878B1
(en)
|
1999-12-10 |
2006-07-11 |
Harris J Milton |
Hydrolytically degradable polymers and hydrogels made therefrom
|
US6413507B1
(en)
|
1999-12-23 |
2002-07-02 |
Shearwater Corporation |
Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
|
RU2278123C2
(ru)
|
2000-02-11 |
2006-06-20 |
Максиджен Холдингз Лтд. |
Молекулы, подобные фактору vii или viia
|
AU2001256148A1
(en)
|
2000-05-03 |
2001-11-12 |
Novo-Nordisk A/S |
Subcutaneous administration of coagulation factor vii
|
AU2001254624A1
(en)
|
2000-05-03 |
2001-11-12 |
Novo-Nordisk A/S |
Human coagulation factor vii variants
|
WO2001093914A2
(en)
|
2000-06-08 |
2001-12-13 |
La Jolla Pharmaceutical Company |
Multivalent platform molecules comprising high molecular weight polyethylene oxide
|
US6423826B1
(en)
|
2000-06-30 |
2002-07-23 |
Regents Of The University Of Minnesota |
High molecular weight derivatives of vitamin K-dependent polypeptides
|
US7118737B2
(en)
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
EP1319067A2
(en)
|
2000-09-13 |
2003-06-18 |
Novo Nordisk A/S |
Human coagulation factor vii variants
|
DE60137950D1
(de)
|
2000-10-02 |
2009-04-23 |
Novo Nordisk Healthcare Ag |
Verfahren zur herstellung vitamin-k-abhängiger proteine
|
GB0103877D0
(en)
*
|
2001-02-16 |
2001-04-04 |
King S College London |
Novel Drug Delivery system
|
AU2002249096B2
(en)
|
2001-03-22 |
2007-06-28 |
Novo Nordisk Health Care Ag |
Coagulation factor VII derivatives
|
US6913915B2
(en)
|
2001-08-02 |
2005-07-05 |
Phoenix Pharmacologics, Inc. |
PEG-modified uricase
|
US6770625B2
(en)
*
|
2001-09-07 |
2004-08-03 |
Nobex Corporation |
Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
|
US7795210B2
(en)
|
2001-10-10 |
2010-09-14 |
Novo Nordisk A/S |
Protein remodeling methods and proteins/peptides produced by the methods
|
US7265084B2
(en)
|
2001-10-10 |
2007-09-04 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
DK1578771T3
(da)
|
2001-10-10 |
2013-06-10 |
Novo Nordisk As |
Remodellering og glycokonjugering af peptider
|
KR100948532B1
(ko)
|
2001-11-07 |
2010-03-23 |
넥타르 테라퓨틱스 |
분지형 중합체 및 그의 공액체
|
DE60228492D1
(de)
|
2001-11-28 |
2008-10-02 |
Neose Technologies Inc |
Remodellierung von glycoproteinen unter verwendung von endoglycanasen
|
EP1461444A2
(en)
|
2001-11-28 |
2004-09-29 |
Neose Technologies, Inc. |
Glycopeptide remodeling using amidases
|
UA86744C2
(en)
|
2002-06-21 |
2009-05-25 |
Ново Нордиск Хэлс Кеа Аг |
Pegylated factor vii glycoforms
|
US7122189B2
(en)
|
2002-08-13 |
2006-10-17 |
Enzon, Inc. |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
|
US7087229B2
(en)
|
2003-05-30 |
2006-08-08 |
Enzon Pharmaceuticals, Inc. |
Releasable polymeric conjugates based on aliphatic biodegradable linkers
|
EP1681303B1
(en)
|
2002-09-11 |
2013-09-04 |
Fresenius Kabi Deutschland GmbH |
HASylated polypeptides, especially HASylated erythropoietin
|
IL166506A0
(en)
|
2002-09-11 |
2006-01-15 |
Fresenius Kabi De Gmbh |
Hasylated polypeptides especially hasylated erythropoietin
|
EP1400533A1
(en)
|
2002-09-11 |
2004-03-24 |
Fresenius Kabi Deutschland GmbH |
HASylated polypeptides, especially HASylated erythropoietin
|
US20040062748A1
(en)
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
ES2308032T5
(es)
|
2002-12-31 |
2017-04-24 |
Nektar Therapeutics |
Derivados poliméricos de ácido maleámico y sus bioconjugados
|
WO2004060965A2
(en)
|
2002-12-31 |
2004-07-22 |
Nektar Therapeutics Al, Corporation |
Hydrolytically stable maleimide-terminated polymers
|
CN1767857A
(zh)
|
2003-02-26 |
2006-05-03 |
尼克塔治疗亚拉巴马公司 |
聚合物-因子ⅷ部分共轭物
|
US7623892B2
(en)
|
2003-04-02 |
2009-11-24 |
Palm, Inc. |
System and method for enabling a person to switch use of computing devices
|
DK1620118T3
(da)
|
2003-04-08 |
2014-09-29 |
Yeda Res & Dev |
Reversible pegylerede lægemidler
|
EP2338333B1
(en)
|
2003-04-09 |
2017-09-06 |
ratiopharm GmbH |
Glycopegylation methods and proteins/peptides produced by the methods
|
US20080206182A1
(en)
|
2003-08-08 |
2008-08-28 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of a Polymer and a Protein Linked by an Oxime Group
|
WO2005014035A2
(en)
|
2003-08-08 |
2005-02-17 |
Novo Nordisk Health Care Ag |
Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
CN1863549A
(zh)
*
|
2003-08-08 |
2006-11-15 |
费森尤斯卡比德国有限公司 |
通过肟连接基团进行连接的聚合物和蛋白质的缀合物
|
WO2005016949A2
(en)
|
2003-08-12 |
2005-02-24 |
Lipoxen Technologies Limited |
Sialic acid derivatives
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
US20070254836A1
(en)
|
2003-12-03 |
2007-11-01 |
Defrees Shawn |
Glycopegylated Granulocyte Colony Stimulating Factor
|
AU2004296860B2
(en)
|
2003-12-03 |
2010-04-22 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
US20060040856A1
(en)
|
2003-12-03 |
2006-02-23 |
Neose Technologies, Inc. |
Glycopegylated factor IX
|
ES2560657T3
(es)
|
2004-01-08 |
2016-02-22 |
Ratiopharm Gmbh |
Glicosilación con unión en O de péptidos G-CSF
|
WO2005092369A2
(en)
|
2004-03-11 |
2005-10-06 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyethyl starch and erythropoietin
|
GB0412181D0
(en)
*
|
2004-06-01 |
2004-06-30 |
Celltech R&D Ltd |
Biological products
|
WO2006020372A2
(en)
|
2004-07-23 |
2006-02-23 |
Neose Technologies, Inc. |
Enzymatic modification of glycopeptides
|
US20090176967A1
(en)
|
2004-08-02 |
2009-07-09 |
Novo Nordisk Healthcare A/G |
Conjugation of FVII
|
US7875708B2
(en)
|
2004-08-12 |
2011-01-25 |
Lipoxen Technologies Limited |
Sialic acid derivatives
|
EP1799249A2
(en)
|
2004-09-10 |
2007-06-27 |
Neose Technologies, Inc. |
Glycopegylated interferon alpha
|
WO2006053299A2
(en)
|
2004-11-12 |
2006-05-18 |
Bayer Healthcare Llc |
Site-directed modification of fviii
|
WO2006069246A2
(en)
|
2004-12-22 |
2006-06-29 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
ES2434035T3
(es)
|
2004-12-27 |
2013-12-13 |
Baxter International Inc. |
Conjugados de polímero-factor von Willebrand
|
JP2008526864A
(ja)
|
2005-01-06 |
2008-07-24 |
ネオス テクノロジーズ インコーポレイテッド |
糖断片を用いる糖結合
|
KR20080013850A
(ko)
*
|
2005-02-08 |
2008-02-13 |
더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 |
면역원성 분자
|
EP2975135A1
(en)
|
2005-05-25 |
2016-01-20 |
Novo Nordisk A/S |
Glycopegylated factor IX
|
EP2279758B1
(en)
|
2005-06-16 |
2015-02-25 |
Nektar Therapeutics |
Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
|
EP2360170A3
(en)
|
2005-06-17 |
2012-03-28 |
Novo Nordisk Health Care AG |
Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
|
EP1919498A2
(en)
|
2005-08-26 |
2008-05-14 |
Maxygen Holdings Ltd. |
Liquid factor vii composition
|
KR20080038391A
(ko)
*
|
2005-08-30 |
2008-05-06 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
페그화 성장 호르몬의 액체 제제
|
EP1962907A2
(en)
|
2005-12-21 |
2008-09-03 |
Wyeth a Corporation of the State of Delaware |
Protein formulations with reduced viscosity and uses thereof
|
AU2007215566A1
(en)
*
|
2006-01-19 |
2007-08-23 |
Ambrx, Inc. |
Non-natural amino acid polypeptides having modulated immunogenicity
|
CA2647314A1
(en)
|
2006-03-31 |
2007-11-08 |
Baxter International Inc. |
Pegylated factor viii
|
US7645860B2
(en)
|
2006-03-31 |
2010-01-12 |
Baxter Healthcare S.A. |
Factor VIII polymer conjugates
|
EP2089052A4
(en)
|
2006-05-24 |
2011-02-16 |
Peg Biosciences |
POLYETHYLENE GLYCOL-BASED LINK COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES BASED ON SAID COMPOUNDS
|
US7939632B2
(en)
|
2006-06-14 |
2011-05-10 |
Csl Behring Gmbh |
Proteolytically cleavable fusion proteins with high molar specific activity
|
PT2049692E
(pt)
|
2006-07-13 |
2016-02-22 |
Serum Inst India Ltd |
Processo para a preparação de ácido polissiálico de elevada pureza
|
WO2008025856A2
(en)
|
2006-09-01 |
2008-03-06 |
Novo Nordisk Health Care Ag |
Modified glycoproteins
|
EP2054521A4
(en)
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
|
WO2008058547A2
(en)
*
|
2006-11-17 |
2008-05-22 |
Nya Hamlet Pharma Ab |
Alpha-lactalbumin composition
|
DK2101821T3
(da)
|
2006-12-15 |
2014-10-06 |
Baxter Healthcare Sa |
Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
|
CA2671851A1
(en)
|
2006-12-28 |
2008-07-10 |
Ambrx, Inc. |
Phenazine and quinoxaline substituted amino acids and polypeptides
|
EP2099475B1
(en)
|
2007-01-03 |
2016-08-24 |
Novo Nordisk Health Care AG |
Subcutaneous administration of coagulation factor viia-related polypeptides
|
WO2008119815A1
(en)
|
2007-04-02 |
2008-10-09 |
Novo Nordisk A/S |
Subcutaneous administration of coagulation factor ix
|
CN101687048B
(zh)
|
2007-06-26 |
2013-02-27 |
巴克斯特国际公司 |
可水解的聚合fmoc-连接体
|
US9333247B2
(en)
|
2007-07-03 |
2016-05-10 |
Children's Hospital & Research Center At Oakland |
Oligosialic acid derivatives, methods of manufacture, and immunological uses
|
WO2009047500A1
(en)
|
2007-10-09 |
2009-04-16 |
Polytherics Limited |
Novel conjugated proteins and peptides
|
EP2070951A1
(en)
|
2007-12-14 |
2009-06-17 |
Fresenius Kabi Deutschland GmbH |
Method for producing a hydroxyalkyl starch derivatives with two linkers
|
JP5647899B2
(ja)
|
2008-01-08 |
2015-01-07 |
ラツィオファルム ゲーエムベーハーratiopharm GmbH |
オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
|
PL2257311T3
(pl)
|
2008-02-27 |
2014-09-30 |
Novo Nordisk As |
Koniugaty cząsteczek czynnika VIII
|
EP2280734B1
(en)
|
2008-04-24 |
2014-02-26 |
Cantab Biopharmaceuticals Patents Limited |
Factor ix conjugates with extended half-lives
|
CN102065899A
(zh)
|
2008-05-23 |
2011-05-18 |
诺沃-诺迪斯克保健股份有限公司 |
含有高浓度的芳香族防腐剂的peg-官能化的丝氨酸蛋白酶的制剂
|
EP2285401A1
(en)
|
2008-05-23 |
2011-02-23 |
Novo Nordisk Health Care AG |
Low viscosity compositions comprising a pegylated gla-domain containing protein
|
KR20110017420A
(ko)
|
2008-06-04 |
2011-02-21 |
바이엘 헬스케어 엘엘씨 |
폰 빌레브란트 질환의 치료를 위한 fviii 뮤테인
|
JP5622117B2
(ja)
|
2008-07-21 |
2014-11-12 |
ポリテリクスリミテッド |
生体分子を接合するための新規な試薬及び方法
|
EP2352515A4
(en)
|
2008-11-03 |
2012-04-25 |
Bayer Healthcare Llc |
METHOD FOR TREATING HEMOPHILIA
|
EP2387413A4
(en)
|
2009-01-19 |
2015-12-23 |
Bayer Healthcare Llc |
PROTEIN CONJUGATE WITH AN ENDOPEPTIDASE-SPLICABLE BIOPROTEKTIVES PART
|
CN102333788A
(zh)
|
2009-02-19 |
2012-01-25 |
诺沃—诺迪斯克有限公司 |
因子viii的修饰
|
US9005598B2
(en)
|
2009-03-04 |
2015-04-14 |
Polytherics Limited |
Conjugated proteins and peptides
|
WO2010120365A2
(en)
|
2009-04-16 |
2010-10-21 |
Wu Nian |
Protein-carrier conjugates
|
US20120134977A1
(en)
|
2009-06-01 |
2012-05-31 |
Yeda Research And Development Co. Ltd. |
Prodrugs containing albumin binding probe
|
EP2461821A4
(en)
|
2009-07-31 |
2013-07-03 |
Bayer Healthcare Llc |
MODIFIED POLYPEPTIDES OF FACTOR IX AND USES THEREOF
|
DE102009028526A1
(de)
|
2009-08-13 |
2011-02-24 |
Leibniz-Institut Für Polymerforschung Dresden E.V. |
Verfahren zur Modifikation und Funktionalisierung von Sacchariden
|
WO2011037896A2
(en)
|
2009-09-25 |
2011-03-31 |
Vybion, Inc. |
Polypeptide modification
|
CN102639553A
(zh)
|
2009-11-24 |
2012-08-15 |
诺沃—诺迪斯克保健股份有限公司 |
纯化聚乙二醇化蛋白质的方法
|
CN102770449B
(zh)
|
2010-02-16 |
2016-02-24 |
诺沃—诺迪斯克有限公司 |
具有降低的vwf结合的因子viii分子
|
EP2536752B1
(en)
*
|
2010-02-16 |
2015-04-08 |
Novo Nordisk A/S |
Modified recombinant Factor VIII
|
GB201007356D0
(en)
|
2010-04-30 |
2010-06-16 |
Leverton Licence Holdings Ltd |
Conjugated factor VIIa
|
GB201007357D0
(en)
|
2010-04-30 |
2010-06-16 |
Leverton Licence Holdings Ltd |
Conjugated factor VIII
|
BR112013001611B1
(pt)
|
2010-07-30 |
2022-05-10 |
Takeda Pharmaceutical Company Limited |
Método para conjugar um polímero solúvel em água a uma fração de carboidrato oxidado de uma proteína terapêutica, proteína terapêutica modificada, método para formar uma ligação oxima entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo amino-óxi ativo emétodo para formar uma ligação hidrazona entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo hidrazida ativo
|
EP2640483A1
(en)
|
2010-11-15 |
2013-09-25 |
Biogen Idec Inc. |
Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
|
RS58578B1
(sr)
|
2011-07-08 |
2019-05-31 |
Bioverativ Therapeutics Inc |
Faktor viii himernih i hibridnih polipeptida i postupci za njihovu upotrebu
|